Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 May 2021
Historique:
received: 25 03 2021
revised: 03 05 2021
accepted: 07 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 10 6 2021
Statut: epublish

Résumé

(1) Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs-besides being important regulators of cancer development-may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein-protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.

Identifiants

pubmed: 34064637
pii: ijms22105058
doi: 10.3390/ijms22105058
pmc: PMC8151942
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating MicroRNA 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Neuro Oncol. 2018 Jan 10;20(1):78-91
pubmed: 29016926
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
OMICS. 2012 Dec;16(12):690-9
pubmed: 23215807
J Pathol. 2010 Jan;220(2):126-39
pubmed: 19882673
Br J Cancer. 2013 Jul 23;109(2):452-61
pubmed: 23807165
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Bioinformatics. 2013 Mar 1;29(5):638-44
pubmed: 23325619
Cancers (Basel). 2012 Sep 03;4(3):846-72
pubmed: 24213470
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Anim Sci Biotechnol. 2012 Jun 01;3(1):12
pubmed: 22958451
Neurochem Res. 2018 Nov;43(11):2047-2054
pubmed: 30203400
Nat Commun. 2017 May 12;8:15223
pubmed: 28497778
J Neurol Sci. 2015 Jan 15;348(1-2):181-7
pubmed: 25510379
Int J Cancer. 2013 Jan 1;132(1):116-27
pubmed: 22674182
J Neurooncol. 2002 Aug;59(1):1-6
pubmed: 12222833
Int J Mol Sci. 2020 Apr 27;21(9):
pubmed: 32349263
J Neurochem. 2011 Aug;118(3):449-57
pubmed: 21561454
CA Cancer J Clin. 2010 May-Jun;60(3):166-93
pubmed: 20445000
Oncol Lett. 2017 Aug;14(2):2353-2358
pubmed: 28781674
RNA Biol. 2015;12(12):1355-63
pubmed: 26488306
Cancer Res. 1980 Dec;40(12):4606-11
pubmed: 7438094
Oncotarget. 2017 Jan 17;8(3):5057-5068
pubmed: 27926502
Pathol Oncol Res. 2020 Apr;26(2):753-763
pubmed: 30806889
Oncol Lett. 2019 Dec;18(6):6171-6179
pubmed: 31788092
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
J Biol Chem. 2010 Jun 4;285(23):17442-52
pubmed: 20353945
Oncotarget. 2017 Jul 21;8(33):55319-55331
pubmed: 28903422
Onco Targets Ther. 2021 Jan 15;14:455-467
pubmed: 33488100
Onco Targets Ther. 2020 Sep 24;13:9513-9523
pubmed: 33061435
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Oncotarget. 2016 Aug 30;7(35):56958-56975
pubmed: 27486972
J Exp Clin Cancer Res. 2009 Jun 16;28:82
pubmed: 19531230
Int J Mol Sci. 2020 Oct 12;21(20):
pubmed: 33053907
Brain Res. 2008 Oct 21;1236:185-93
pubmed: 18710654
World J Gastroenterol. 2012 Oct 14;18(38):5442-53
pubmed: 23082062
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
J Exp Clin Cancer Res. 2019 Jan 25;38(1):36
pubmed: 30683134
Nucleic Acids Res. 2011 Jan;39(Database issue):D163-9
pubmed: 21071411
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
Front Neurol. 2021 Feb 01;11:610163
pubmed: 33597912
Aliment Pharmacol Ther. 2010 Aug;32(3):487-97
pubmed: 20497147
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Br J Cancer. 2002 Jun 17;86(12):1899-904
pubmed: 12085183
PLoS One. 2018 Feb 14;13(2):e0189452
pubmed: 29444091
Clin Cancer Res. 2010 Apr 15;16(8):2443-9
pubmed: 20371685
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812
J Biotechnol. 2019 Jun 10;298:82-87
pubmed: 30986516

Auteurs

Dóra Géczi (D)

Department of Human Genetics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Bálint Nagy (B)

Department of Human Genetics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Melinda Szilágyi (M)

Department of Human Genetics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

András Penyige (A)

Department of Human Genetics, Faculty of Medicine, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Álmos Klekner (Á)

Department of Neurosurgery, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Adrienn Jenei (A)

Department of Neurosurgery, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

József Virga (J)

Department of Oncology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Zsuzsanna Birkó (Z)

Department of Human Genetics, Faculty of Medicine, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH